Welcome to our dedicated page for Dbv Technologies S A news (Ticker: DBVT), a resource for investors and traders seeking the latest updates and insights on Dbv Technologies S A stock.
DBV Technologies S.A. develops treatment options for food allergies and other immunologic conditions as a late-stage biopharmaceutical company. Company updates center on the proprietary VIASKIN® patch technology, epicutaneous immunotherapy, and the VIASKIN Peanut program for peanut-allergic toddlers and children.
Recurring developments include clinical data from the Phase 3 VITESSE study, annual and quarterly financial results, financing and warrant-related capital actions, leadership and governance changes, share and voting-rights disclosures under French market rules, and market information tied to DBVT American Depositary Shares.
DBV Technologies, a clinical-stage biopharmaceutical company, announced that all resolutions proposed at its 2024 Combined General Meeting were approved by shareholders. The meeting, chaired by Michel de Rosen, took place on May 16, 2024, in Châtillon, France. The resolutions cover various strategic and operational plans aimed at advancing DBV's focus on treatments for food allergies and immunologic conditions with significant unmet needs. Detailed results are available on the company's website.
DBV Technologies, a biopharmaceutical company, will participate in two investor conferences in May 2024. The CEO will present at the Citizens JMP Life Sciences Conference on May 13 and the H.C. Wainwright BioConnect Conference on May 20. The presentations will be available via live webcast on the company's website.
DBV Technologies, a biopharmaceutical company, released its First Quarter 2024 Financial Results and Business Update. The company reported a cash balance of $101.5 million, with VITESSE Phase 3 study enrollment progressing well. Robert Pietrusko was appointed Chief Regulatory Officer. Financially, the company saw a net cash decrease due to operating activities, and faces uncertainties in sustaining operations.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.